Hypothesis: Chronic SASP signaling from senescent cells drives the formation of a HIF‑1α/NF‑κB heterocomplex that directly binds the NAMPT promoter, recruits DNMT3A, and imposes a repressive methylation lock that sustains NAD+ decline. Low NAD+ diminishes SIRT1 deacetylase activity, allowing HIF‑1α to accumulate even under normoxia; HIF‑1α then cooperates with NF‑κB p65 (activated by IL‑1β, TNF‑α, and IL‑6) to occupy cis‑regulatory elements upstream of NAMPT. This cooperative binding brings DNMT3A to the promoter, leading to CpG methylation and stable transcriptional silencing. The resulting NAD+ deficit further fuels mitochondrial ROS and SASP production, creating a self‑reinforcing loop that locks cells into a low‑energy, pro‑inflammatory state.

Key predictions:

1. In aged mouse liver and human adipose tissue, sequential ChIP‑reChIP will detect HIF‑1α and NF‑κB p65 co‑occupancy at the NAMPT promoter and an adjacent enhancer, accompanied by elevated DNMT3A binding and increased 5‑mC levels at specific CpGs.
2. Pharmacological inhibition of HIF‑1α (PX‑478) or selective blockade of IKKβ (thus NF‑κB) in 24‑month‑old mice will raise hepatic NAMPT mRNA by ≥2‑fold, elevate NAD+ concentrations to youthful levels, and reduce SASP cytokines (IL‑6, MCP‑1) without changing CD38 expression or activity.
3. CRISPR‑Cas9 deletion of a 12‑bp motif containing the predicted HIF‑1α/NF‑κB cooperative site in the NAMPT promoter of human iPSC‑derived fibroblasts will abolish age‑associated NAD+ decline after 60 days of culture, whereas a scrambled control edit will show the typical decline.
4. DNMT3A knock‑down via siRNA or catalytic inhibition with RG108 will prevent promoter methylation and restore NAMPT expression in senescent cells even when HIF‑1α/NF‑κB are chemically stabilized, indicating that methylation is the downstream effector of transcriptional repression.
5. Single‑cell multi‑omics (scATAC‑seq + scRNA‑seq) from aged tissues will reveal a subpopulation of cells with high HIF‑1α/NF‑κB activity, low NAMPT transcript, high SASP signature, and promoter methylation, linking the molecular circuit to the phenotypic SASP state.

These predictions are falsifiable: if co‑occupancy of HIF‑1α and NF‑κB at the NAMPT promoter is not detectable in aging, or if pharmacological/genetic disruption of the complex fails to raise NAMPT, NAD+, or lower SASP, the hypothesis would be refuted. Conversely, observation of the predicted binding, methylation, and functional rescue would support a model in which NAD+ decline is an actively programmed epigenetic downgrade rather than a passive byproduct of oxidative damage.

Supporting evidence: Chronic inflammatory cytokines suppress NAMPT while elevating CD38 1 2. Genetic deletion of CD38 prevents age‑related NAD+ decline [1]. Declining nuclear NAD+ reduces SIRT1 activity, leading to HIF‑1α stabilization under normoxia 3. The NAMPT‑NAD+ axis modulates the pro‑inflammatory SASP via AMPK and NF‑κB 4. Age‑related hypermethylated regions are enriched for ARNT/HIF‑1β motifs 5, suggesting HIF complex shapes the aging epigenome. Low NAMPT precedes metabolic complications through chronic inflammation 6 and NAD+ restoration rejuvenates senescent stem cells by enhancing SIRT1 activity 7.